GSK plc (LSE/NYSE: GSK) has unveiled a landmark commitment to invest $30 billion across the United States over the next five years, focused on strengthening research and development as well as supply chain infrastructure. This bold investment underscores GSK’s ambition to accelerate life sciences innovation in the U.S. while reinforcing the country’s role as a global leader in advanced biopharmaceutical research and manufacturing.
Within this plan, GSK announced today a new $1.2 billion investment aimed at building state-of-the-art biopharma manufacturing facilities, powered by artificial intelligence and advanced digital technologies. These initiatives will support the delivery of next-generation laboratories and flexible factories designed to bring forward transformative new treatments. The investment will generate hundreds of highly skilled jobs across the U.S., further expanding GSK’s strong workforce of approximately 15,000 employees in the country.
A major component of this investment is the construction of a new biologics flex factory at Upper Merion, Pennsylvania. Slated to begin construction in 2026, the facility will focus on developing medicines for respiratory diseases such as COPD and asthma, as well as innovative treatments for a range of cancers including haematological, gynaecological, lung, and other solid tumors. GSK is also introducing advanced digital capabilities and AI-driven systems across its five existing U.S. manufacturing sites, located in Pennsylvania, North Carolina, Maryland, and Montana. Additional expansions include enhanced drug substance manufacturing and improvements to device and auto-injector production and assembly.
The broader $30 billion commitment also encompasses increased investment in early-stage drug discovery, clinical development, and trial activity. Over the next five years, the U.S. is expected to become GSK’s leading global hub for clinical trials, with the highest number of studies, sites, and participants. This builds upon GSK’s recent manufacturing momentum, including the $800 million expansion at its Marietta, Pennsylvania facility launched in 2024, which doubled the site’s capacity.
Emma Walmsley, Chief Executive Officer of GSK, said: “Alongside the many longstanding and vital shared interests that connect the U.K. and the United States is advancing life sciences to get ahead of disease. This State Visit highlights the strong collaboration between two countries that have consistently led in science and healthcare innovation, and we are proud to play a part in both. Today’s $30 billion investment in the U.S. over the next five years further strengthens our R&D and supply chain capabilities, including a $1.2 billion next-generation biologics factory that combines AI, advanced technology, and expert talent to bring forward transformational respiratory and cancer medicines for patients in America.”
Through its expanding global network, GSK delivered 1.7 billion packs of medicines and more than 400 million vaccine doses in the past year. These continued investments in the U.S. reflect GSK’s mission to positively impact the health of 2.5 billion people worldwide by 2030.
